Baxter International Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $38.22
- Today's High:
- $38.945
- Open Price:
- $38.94
- 52W Low:
- $37.0791
- 52W High:
- $71.8518
- Prev. Close:
- $38.7
- Volume:
- 2098699
Company Statistics
- Market Cap.:
- $21.07 billion
- Book Value:
- 11.622
- Revenue TTM:
- $15.05 billion
- Operating Margin TTM:
- 11.64%
- Gross Profit TTM:
- $6.03 billion
- Profit Margin:
- -16.34%
- Return on Assets TTM:
- 3.59%
- Return on Equity TTM:
- -32.52%
Company Profile
Baxter International Inc had its IPO on 1981-10-27 under the ticker symbol BAX.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Baxter International Inc has a staff strength of 60,000 employees.
Stock update
Shares of Baxter International Inc opened at $38.94 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $38.22 - $38.95, and closed at $38.33.
This is a -0.96% slip from the previous day's closing price.
A total volume of 2,098,699 shares were traded at the close of the day’s session.
In the last one week, shares of Baxter International Inc have slipped by -5.59%.
Baxter International Inc's Key Ratios
Baxter International Inc has a market cap of $21.07 billion, indicating a price to book ratio of 4.7926 and a price to sales ratio of 1.736.
In the last 12-months Baxter International Inc’s revenue was $15.05 billion with a gross profit of $6.03 billion and an EBITDA of $3.09 billion. The EBITDA ratio measures Baxter International Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Baxter International Inc’s operating margin was 11.64% while its return on assets stood at 3.59% with a return of equity of -32.52%.
In Q1, Baxter International Inc’s quarterly earnings growth was a negative -37.8% while revenue growth was a negative 1.6%.
Baxter International Inc’s PE and PEG Ratio
- Forward PE
- 14.2653
- Trailing PE
- 0
- PEG
- 1.6956
Its diluted EPS in the last 12-months stands at $-4.95 per share while it has a forward price to earnings multiple of 14.2653 and a PEG multiple of 1.6956. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Baxter International Inc’s profitability.
Baxter International Inc stock is trading at a EV to sales ratio of 2.8366 and a EV to EBITDA ratio of -68.32. Its price to sales ratio in the trailing 12-months stood at 1.736.
Baxter International Inc stock pays annual dividends of $1.16 per share, indicating a yield of 2.81% and a payout ratio of 36.71%.
Balance sheet and cash flow metrics
- Total Assets
- $28.29 billion
- Total Liabilities
- $4.76 billion
- Operating Cash Flow
- $-170000000.00
- Capital Expenditure
- $172 million
- Dividend Payout Ratio
- 36.71%
Baxter International Inc ended 2024 with $28.29 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $28.29 billion while shareholder equity stood at $5.88 billion.
Baxter International Inc ended 2024 with $0 in deferred long-term liabilities, $4.76 billion in other current liabilities, 683000000.00 in common stock, $13.95 billion in retained earnings and $6.87 billion in goodwill. Its cash balance stood at $1.67 billion and cash and short-term investments were $1.67 billion. The company’s total short-term debt was $1,153,000,000 while long-term debt stood at $15.28 billion.
Baxter International Inc’s total current assets stands at $8.10 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.55 billion compared to accounts payable of $1.29 billion and inventory worth $2.92 billion.
In 2024, Baxter International Inc's operating cash flow was $-170000000.00 while its capital expenditure stood at $172 million.
Comparatively, Baxter International Inc paid $0.37 in dividends in 2024.
Other key metrics
- Current Trading Price
- $38.33
- 52-Week High
- $71.8518
- 52-Week Low
- $37.0791
- Analyst Target Price
- $50.93
Baxter International Inc stock is currently trading at $38.33 per share. It touched a 52-week high of $71.8518 and a 52-week low of $71.8518. Analysts tracking the stock have a 12-month average target price of $50.93.
Its 50-day moving average was $43.48 and 200-day moving average was $43.76 The short ratio stood at 0.94 indicating a short percent outstanding of 0%.
Around 24.3% of the company’s stock are held by insiders while 8398.6% are held by institutions.
Frequently Asked Questions About Baxter International Inc
Similar Industry Stocks (Medical Instruments & Supplies)
Most Active
Top Gainers
Top Losers
About
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules; and a collaborative research agreement with Miromatrix Medical Inc. to develop treatments for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is based in Deerfield, Illinois.